The microbiome contract development and manufacturing organization (CDMO) is developing the Boxborough site in phases, and work on the first two phases has already begun. Construction is underway, and operations of good manufacturing practice (GMP) suites are expected in early 2022. The facility will employ over 150 people and will have a flexible design with dedicated lab and GMP capacity to support commercial products or pipeline products for clients.

Image courtesy of Arranta Bio.

GMP manufacturing suites will accommodate product-specific processing requirements for both drug substance and finished drug products. Initially, Arranta will provide clients with up to multiple 2,000-L scale single-use bioreactors for anaerobic bacteria or 1,000-L scale single-use fermenters for aerobic bacteria and fully automated drug product manufacturing. The company plans to add secondary packaging and labeling capabilities at the facility.

The total investment in the facility is expected to exceed $150 million. The company announced that it closed an oversubscribed series B equity financing from current investors to fund the expansion.